Myasthenia gravis
Conditions
Interventions
Treatment group of traditional Chinese medicine hospital:NA
Treatment Group of Western Hospital:NA
Sponsors
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
14 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis 2020 or meet the diagnostic criteria of traditional Chinese medicine; (2) Patients with myasthenia gravis who meet the clinical classification of MGFA type I, II (IIa, IIb), and III (IIIa, IIIb); (3) Age range from 14 to 85 years old, did not use Chinese or Western medicine treatment drugs at the initial diagnosis, or did not use Chinese or Western medicine treatment drugs for more than a week; (4) Not accompanied by severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, or intestinal diseases (such as acute inflammation, tumors, severe infections, etc.); (5) Female non pregnancy and lactation period; (6) Agree to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the inclusion criteria; (2)Patients who have been taking other Western medicines for the treatment of myasthenia gravis, other than bromopyridamine tablets, prednisone acetate, and tacrolimus, as well as any other traditional Chinese medicine or Western medicine that affects the gut microbiota (such as antibiotics), for more than a week. (3) Pregnant or lactating women; (4) Patients with allergies or contraindications to the ingredients of bromopyridamine tablets, prednisone acetate, tacrolimus, and traditional Chinese medicine decoction; (5) Combined with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, or intestinal diseases (such as acute inflammation, tumors, severe infections, etc.); (6) Participants in clinical trials of other drugs simultaneously. Those who meet any of the above criteria will be excluded.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| MG-absolute and relative scoring system (ARS-MG) scores;The 15-item MG Quality of Life (MG-QOL15) scores;MG-specific manual muscle test (MMT);The Myasthenia Gravis activities of daily living profile (MG-ADL) scores;Intestinal microbiota sequence;Serum AChR-Ab titers;Time and dosage of Western medicine reduction or even discontinuation; | — |
Primary
| Measure | Time frame |
|---|---|
| MGFA post-intervention status;Quantitative Myasthenia Gravis (QMG) scores; | — |
Countries
China
Contacts
Public ContactQiao Wenjun
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Outcome results
None listed